3,591 reports of this reaction
7.3% of all PAZOPANIB HYDROCHLORIDE reports
#2 most reported adverse reaction
DIARRHOEA is the #2 most commonly reported adverse reaction for PAZOPANIB HYDROCHLORIDE, manufactured by Novartis Pharmaceuticals Corporation. There are 3,591 FDA adverse event reports linking PAZOPANIB HYDROCHLORIDE to DIARRHOEA. This represents approximately 7.3% of all 49,320 adverse event reports for this drug.
Patients taking PAZOPANIB HYDROCHLORIDE who experience diarrhoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DIARRHOEA is moderately reported among PAZOPANIB HYDROCHLORIDE users, representing a notable but not dominant share of adverse events.
In addition to diarrhoea, the following adverse reactions have been reported for PAZOPANIB HYDROCHLORIDE:
The following drugs have also been linked to diarrhoea in FDA adverse event reports:
DIARRHOEA has been reported as an adverse event in 3,591 FDA reports for PAZOPANIB HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DIARRHOEA accounts for approximately 7.3% of all adverse event reports for PAZOPANIB HYDROCHLORIDE, making it one of the most commonly reported side effect.
If you experience diarrhoea while taking PAZOPANIB HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.